拓扑替康

Description

Topotecan · CAS 123948-87-8 · C23H23N3O5. UNII 7M7YKX2N15. Melting Point: 213-218 °C; Melting Point: 213 - 218 °C; Solubility: 8.61e-01 g/L.

Identification

CAS Registry Number	123948-87-8
PubChem CID	60700
Molecular formula	C23H23N3O5
IUPAC name	(19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
UNII (FDA)	7M7YKX2N15

Computed Descriptors

Molecular Weight	421.4
XLogP3	0.5
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	3
Exact Mass	421.16377084
Monoisotopic Mass	421.16377084
Topological Polar Surface Area	103
Heavy Atom Count	31
Formal Charge	0

Physical & Chemical Properties

Melting Point	213-218 °C
Melting Point	213 - 218 °C
Solubility	8.61e-01 g/L
LogP	0.8
LogP	0.91

Physical description & handling notes

• Solid
• Stable under recommended storage conditions.
• Hazardous decomposition products: Hazardous decomposition products formed under fire conditions. - Carbon oxides, nitrogen oxides (NOx), hydrogen chloride gas.
• 223.05 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
• 209.99 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
• Light yellow to greenish powder, mp 213-218 °C (decomposes). Soluble in water up to 1 mg/mL. Hygroscopic. Heant and light sensitive /Topotecan hydrochloride/

GHS Hazard Classification

Reported hazard statements	H301 (18.8%), H315 (20.8%), H319 (20.8%), H335 (18.8%), H340 (18.8%), H341 (79.2%)

Documented Uses

• THERAPEUTIC CATEGORY: Antineoplastic
• Consumption (g per capita) in the USA (2002): 7.59e-07
• Topotecan is semisynthetically manufactured from the plant-derived alkaloid camptothecin. The starting material may be obtained from two natural sources - Chinese (Acuminata) and Indian (Mappia). Purification of the crude extract from either source is required. The main steps in the synthesis involve reduction and selective oxidation of the quinoline moiety of camptothecin, followed by the introduction of an N,N-dimethylaminomethyl side-chain.
• Preparation: J. C. Boehm et al., European Patent Office patent 321122,; eidem, United States of America patent 5004758 (1989, 1991 both to SmithKline Beecham).
• For the treatment of advanced ovarian cancer in patients with disease that has recurred or progressed following therapy with platinum-based regimens. Also used as a second-line therapy for treatment-sensitive small cell lung cancer, as well as in combination with cisplatin for the treatment of stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment with surgery and/or radiation therapy.
• Breast Feeding; Lactation; Antineoplastic Agents; Topoisomerase I Inhibitors

Synonyms

topotecan; 123948-87-8; Hycamptamine; Topotecan lactone; Nogitecan; Hycamptin; Topotecane; (S)-Topotecan; Topotecanum; Topophore C; TopoCED; SKF-104864-A; 9-Dimethylaminomethyl-10-hydroxycamptothecin; NSC-641007; SKF-104864; 7M7YKX2N15

Frequently Asked Questions

What are the CAS number and molecular formula of Topotecan?

CAS 123948-87-8; molecular formula C23H23N3O5; molecular weight — g/mol.

What other names is Topotecan known by?

topotecan, 123948-87-8, Hycamptamine, Topotecan lactone, Nogitecan, Hycamptin.

Is Topotecan classified as hazardous?

Hazard statements reported: H301, H315, H319, H335, H340.

What are the key physical properties of Topotecan?

Melting Point: 213-218 °C; Melting Point: 213 - 218 °C; Solubility: 8.61e-01 g/L; LogP: 0.8.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.